摘要
类器官技术通过三维体外培养高度模拟人体组织器官的结构和功能特征,在疾病模型构建、精准医疗和药物研发等领域具有重要价值。类器官技术在2019年被The New England Journal of Medicine评为优秀的临床前疾病模型,随着研究的不断深入,肿瘤类器官已广泛覆盖多种实体瘤。然而,目前中国在肿瘤类器官的样本采集、培养体系、质量控制及合规治理等关键环节尚缺乏统一的技术规范和共识框架,限制了研究成果的可重复性和临床转化应用。为此,本共识由上海市抗癌协会类器官专业委员会、中国医师协会临床精准医疗专业委员会等组织,基于广泛的国内外文献检索、证据分级及专家审议形成,首次系统性地提出肿瘤类器官构建技术的全流程通用规范,涵盖从样本采集、处理,到类器官培养、传代、冻存、复苏及质量控制全流程。希望通过本共识,能够为从事肿瘤类器官研究的科研人员和临床工作者提供科学的技术指导框架,以提高模型的保真度和可靠性,促进数据共享和横向比较,加速类器官技术在肿瘤精准诊疗中的规范化落地。本共识将根据未来开展的基于类器官的各项研究成果和实践经验定期更新。
Organoid technology,which enables three-dimensional in vitro culture to closely recapitulate key structural and functional features of human tissues and organs,has significant value in disease modeling,precision medicine,and drug discovery and development.With continued advances in organoid research,tumor organoids have been established for a wide range of solid tumors,and the technology was highlighted by The New England Journal of Medicine in 2019 as an excellent preclinical disease model.However,in China,unified technical guidelines and a consensus framework are still lacking for critical aspects of tumor organoid practice,including specimen collection,culture systems,quality control,and compliance governance.This has limited the reproducibility of research findings and their clinical translation.To address these gaps,this consensus was developed by the Organoid Professional Committee of the Shanghai Anticancer Association and Clinical Precision Medicine Professional Committee of Chinese Medical Doctor Association,among others,based on extensive searches of domestic and international literature,evidence grading,and expert review.For the first time,it systematically proposes a full-process general framework for tumor organoid construction,covering specimen collection and processing,organoid culture and passaging,cryopreservation and recovery,and quality control throughout the entire workflow.This consensus is intended to provide a scientific and practical technical guidance framework for researchers and clinicians engaged in tumor organoid studies,improve model fidelity and reliability,facilitate data sharing and cross-study comparability,and accelerate the standardized implementation of organoid technology in precision oncology.The consensus will be updated periodically in accordance with emerging evidence and accumulated practical experience from organoid-based research.
出处
《中国癌症杂志》
北大核心
2026年第3期299-312,共14页
China Oncology
基金
国家自然科学基金(82473011,82273370,U21A20376)。
关键词
类器官
肿瘤
通用规范
全流程
共识
Organoids
Tumor
General guidelines
End-to-end workflow
Consensus
